The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | Preclinical safety and efficacy of CD123-NK cell engager in R/R AML
Anthony Stein, MD, City Of Hope, Duarte, CA, comments on preclinical studies evaluating the safety and efficacy of CD123-directed natural killer (NK) cell engager therapy in acute myeloid leukemia (AML). Dr Stein explains that NK cells have been shown to have a similar profile when compared to T-cell engagers and lead to significant depletion of CD123-positive cells. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
